Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Wilding, J.
Right arrow Articles by Finer, N.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Weight management and cardiovascular disease: implications of recent and ongoing clinical trials

John Wilding

Diabetes and Endocrinology Clinical Research Group, University Hospital Aintree, Liverpool, UK, j.p.h.wilding{at}liv.ac.uk

Nick Finer

Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK

Obesity is a global issue with increasing evidence that overweight and obesity are associated with a higher chronic disease risk. Despite over 10 years of government recognition of a need to develop and implement effective prevention strategies, all age groups are getting fatter with overweight becoming the `norm'. Modest weight loss reduces many of the risk factors that accompany obesity, notably type 2 diabetes, hypertension and dyslipidaemia. Adherence to lifestyle changes required to achieve these improvements is poor and progressively more weight-loss medications are used as adjunctive therapy, while bariatric surgery is performed for the severely obese.

Currently available pharmacotherapy shows encouraging benefits in clinical trials but remains unproven as an effective strategy to support long-term weight loss and weight maintenance and for translation of improved surrogate risk markers into fewer cardiovascular events and a longer life. Three large clinical trials are ongoing in an attempt to answer this question. Br J Diabetes Vasc Dis 2008; 8: 170—176

Key Words: obesity • orlistat • sibutramine • rimonabant • cardiovascular outcomes

The British Journal of Diabetes & Vascular Disease, Vol. 8, No. 4, 170-176 (2008)
DOI: 10.1177/1474651408094587
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 British Journal of Diabetes & Vascular DiseaseHome page
H. Purcell and C. Day
Achieving acceptable adiposity
The British Journal of Diabetes & Vascular Disease, July 1, 2008; 8(4): 159 - 161.
[PDF]